Melanotan II (commonly called MT-2) is a synthetic peptide that mimics a natural hormone in the body to darken skin, suppress appetite, and trigger sexual arousal. It was originally developed at the University of Arizona in the 1990s as a potential way to prevent skin cancer by stimulating the body’s own pigment production, but it was never approved for medical use in any country. Despite this, MT-2 has found a thriving underground market among people chasing a deeper tan without prolonged sun exposure, and the range of effects it produces on the body goes well beyond skin color.
What MT-2 Actually Is
MT-2 is a cyclic heptapeptide, meaning it is a short chain of seven amino acids arranged in a ring shape. It was designed to be a laboratory-modified version of alpha-melanocyte-stimulating hormone (α-MSH), a naturally occurring hormone that tells your pigment-producing skin cells to make melanin. Early preformulation work described it as a compound that “tans the skin” and was being evaluated for the prevention of sunlight-induced skin cancers.1PubMed. Preformulation studies with melanotan-II: a potential skin cancer chemopreventive peptide The idea was that if you could get the skin to produce its own protective pigment, you might reduce UV damage without needing actual sun exposure. That concept never made it through clinical development, but the peptide itself escaped the lab.
Unlike a pill or a cream, MT-2 is typically self-administered by subcutaneous injection, though nasal spray formulations also circulate. It is sold as a lyophilized powder (freeze-dried) that users reconstitute with bacteriostatic water before injecting into belly fat or another subcutaneous site. None of these products go through pharmaceutical quality control, which creates a layer of risk that sits on top of the peptide’s own biological effects.
How MT-2 Produces a Tan
Your skin color depends heavily on melanin, a pigment made by specialized cells called melanocytes. When UV light hits your skin, your body releases α-MSH, which binds to a receptor on melanocytes called the melanocortin 1 receptor (MC1R). That binding kicks off a chain of events inside the cell that leads to production of eumelanin, the dark brown-black pigment responsible for a classic tan. MT-2 mimics α-MSH but is far more potent, and it activates MC1R regardless of whether you have been in the sun. A case report described this as stimulating eumelanin production and resulting in skin pigmentation independent of sun exposure.2PubMed Central. Changes in Oral Mucosa Associated with Melanotan II Injections: A Case Report
Research on human skin cells has confirmed that the compound significantly increases the eumelanin content of skin, even in people who carry genetic variants of MC1R that typically make them poor tanners.3PubMed. Effect of MELANOTAN, [Nle(4), D-Phe(7)]-alpha-MSH, on melanin synthesis in humans with MC1R variant alleles This is part of the appeal for fair-skinned people who burn easily: MT-2 can produce pigmentation that their genetics would not normally allow. However, the pigmentation is not always even. Users frequently report a patchy or “dirty” looking tan, particularly in areas like the face, and existing freckles or moles can darken disproportionately.
Effects Beyond Skin Color
MT-2 is what researchers call a nonselective melanocortin receptor agonist. Your body has five different melanocortin receptors (MC1R through MC5R), and while MT-2 was designed to hit MC1R for tanning, it also activates the others. Because it can cross the blood-brain barrier, it reaches receptors in the central nervous system that control appetite, sexual arousal, and cardiovascular function.4PubMed Central. An overview of benefits and risks of chronic melanocortin‐1 receptor activation This nonselective binding explains why the side-effect profile is so broad.
Appetite Suppression
Animal studies have shown that MT-2 is a potent appetite suppressor. In one controlled experiment, the peptide suppressed food intake in a dose-dependent way, meaning higher doses led to greater appetite reduction. Interestingly, even after the animals returned to normal eating patterns, their body mass remained persistently lower, and they showed less body fat than control animals weeks later.5PubMed Central. Activation of the central melanocortin system chronically reduces body mass without the necessity of long-term caloric restriction This effect occurs through MC3R and MC4R in brain regions that regulate energy balance. In humans, the appetite-suppressing effect is one of the most commonly reported experiences during an injection course, though no controlled human trials have been conducted to quantify it.
Sexual Arousal
One of the most noticeable off-target effects of MT-2 is its ability to induce sexual arousal. In men, this frequently manifests as spontaneous erections occurring one to five hours after injection, sometimes accompanied by an unusual yawning-and-stretching reflex. This effect, driven by melanocortin receptor activation in the brain, was considered so pharmacologically interesting that researchers eventually developed a derivative of MT-2 specifically for sexual dysfunction. That derivative, called bremelanotide (PT-141), is the carboxylate form of the MT-2 molecule and has gone through formal clinical trials.6PubMed Central. Melanocortin receptors, melanotropic peptides and penile erection Bremelanotide was eventually FDA-approved in 2019 under the brand name Vyleesi for hypoactive sexual desire disorder in premenopausal women, making it one of the few pharmaceutical success stories to emerge from this line of research.
Common Short-Term Side Effects
Even at doses typically used by recreational users, MT-2 produces a predictable cluster of short-term side effects. The most frequently reported include:
- Nausea: Often occurs within the first hour after injection and is the most common reason new users reduce their dose.
- Facial flushing: A warm, reddened flush across the face that can last 30 minutes to several hours.
- Reduced appetite: The brain-mediated suppression described above, which can be pronounced enough to make eating feel unpleasant.
- Spontaneous erections: In males, sometimes severe enough to qualify as priapism, typically accompanied by the distinctive yawning reflex.
- Fatigue and lethargy: Particularly in the hours following injection.
These effects tend to diminish with continued use, and many users start with very low doses and gradually increase to minimize nausea in particular. But the short-term side effects, while unpleasant, are not the primary safety concern with MT-2. The more serious risks involve what the peptide does to your skin and cardiovascular system over time.
Mole Changes and Dysplastic Nevi
Because MT-2 indiscriminately stimulates all melanocytes, it does not just tan normal skin. It also activates the melanocytes in existing moles, causing them to darken, enlarge, and sometimes change shape. This is particularly concerning from a dermatological standpoint, because sudden changes in moles are exactly what doctors look for when screening for melanoma.
In one published case, a 25-year-old man developed more than 100 melanocytic nevi (moles), mainly on his back, after a four-week course of subcutaneous MT-2. He had also been using a tanning bed. Many of the moles were clinically atypical, and when dermatologists removed the 10 most suspicious-looking lesions, pathology revealed them to be dysplastic nevi, with three showing severe dysplasia.7Actas Dermo-Sifiliográficas. Eruptive Dysplastic Nevi Following Melanotan Use Dysplastic nevi are not cancer, but severely dysplastic moles occupy an uncomfortable gray zone. They carry a higher statistical risk of eventually progressing, and their appearance can make melanoma screening nearly impossible because every mole looks suspicious.
A separate report described a 16-year-old girl who developed widespread darkening of existing moles and an enlarging nevus in her groin after combining MT-2 injections with tanning bed sessions. She also had a family history of melanoma (FAMMM syndrome), adding genetic risk on top of the peptide-induced changes.8PubMed Central. Changes of melanocytic lesions induced by Melanotan injections and sun bed use in a teenage patient with FAMMM syndrome The pattern across published cases is consistent: MT-2 forces melanocytes into overdrive, and if you combine that stimulation with UV exposure from tanning beds, you are compounding the biological insult to your skin.
Melanoma Concerns
The relationship between MT-2 and melanoma remains the most alarming open question around this peptide. No large epidemiological study has definitively proven that MT-2 causes melanoma, but a growing number of case reports have documented melanoma diagnoses in MT-2 users, and the biological plausibility is hard to ignore.
One case involved a patient who was diagnosed with cutaneous melanoma after a three-to-four-week course of MT-2 injections combined with tanning bed use. The lesion was excised and confirmed as melanoma on histology.9PubMed. Melanoma associated with the use of melanotan-II A more recent and striking report described a 22-year-old woman who developed a mass in her upper jaw after using MT-2 as a nasal spray. Histological analysis confirmed it as a mucosal malignant melanoma, which is an extremely rare cancer in someone that young.10PubMed. Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma? Mucosal melanoma in the mouth is unusual under any circumstances, and its occurrence in a young nasal-spray user raises the possibility that the peptide’s effects extend to melanocytes in the mucous membranes, not just the skin.
The honest scientific picture here is that case reports cannot prove causation. A person who uses MT-2 and also uses tanning beds is already exposing themselves to a known carcinogen (UV radiation), so disentangling the peptide’s contribution from the UV damage is difficult. But the accumulating reports, the biological mechanism (forced melanocyte activation), and cases like the oral melanoma in a 22-year-old keep the concern very much alive. No regulatory body has cleared MT-2 as safe, and the melanoma signal is a major reason why.
Cardiovascular and Serious Systemic Risks
Beyond skin-related concerns, MT-2 has measurable effects on the cardiovascular system. In animal studies, MT-2 and related α-MSH analogues increased both blood pressure and heart rate in a dose-dependent manner, with the heart rate increase being more prominent. These effects were abolished when researchers blocked MC3 and MC4 receptors, confirming that the cardiovascular changes are driven by the same melanocortin receptor system that produces the tanning and appetite effects.11PubMed. Hemodynamic actions and mechanisms of systemically administered α-MSH analogs in mice For most young, healthy users, a temporary bump in heart rate and blood pressure is unlikely to cause an emergency. But for anyone with undiagnosed hypertension or a cardiac condition, the margin of safety is unknown.
More alarming are the reports of severe systemic toxicity. One published case documented a patient who developed rhabdomyolysis (a breakdown of muscle tissue that releases damaging proteins into the bloodstream) and kidney dysfunction after injecting MT-2.12PubMed. Melanotan II injection resulting in systemic toxicity and rhabdomyolysis Rhabdomyolysis is a medical emergency that can lead to permanent kidney damage or death if untreated. A separate review confirmed that rhabdomyolysis and renal failure are among the recognized complications of MT-2 use.13PubMed Central. Melanotan II: a possible cause of renal infarction: review of the literature and case report These are rare events, but the fact that they have occurred at doses people self-administer recreationally is sobering.
How MT-2 Compares to Related Compounds
MT-2 is often confused with two related but distinct compounds: Melanotan I and bremelanotide (PT-141). Understanding the differences matters because they have very different risk profiles.
Melanotan I (also called afamelanotide) is a linear peptide that selectively targets MC1R. Because it is selective, it produces skin darkening without most of the central nervous system effects of MT-2. Afamelanotide has actually been approved in Europe and Australia as a medical treatment for people with erythropoietic protoporphyria, a painful condition that makes them extremely sensitive to light. It is administered as a slow-release implant under medical supervision. MT-2, by contrast, is nonselective, unregulated, and self-injected. The two share a pharmacological ancestor but occupy completely different worlds in terms of safety evidence and oversight.
Bremelanotide, as mentioned earlier, is a metabolite of MT-2 that was isolated and developed specifically for its pro-sexual effects through MC3R and MC4R activation in the brain.6PubMed Central. Melanocortin receptors, melanotropic peptides and penile erection It went through full clinical trials, received FDA approval, and is prescribed at controlled doses with known side effects. When people describe MT-2 as a “two-in-one tanning and libido drug,” they are essentially describing the unrefined parent compound of what was later split into two separate pharmaceutical programs: one for pigmentation (afamelanotide) and one for sexual function (bremelanotide). Using MT-2 gives you both effects simultaneously, plus everything else that comes with nonselective melanocortin activation, at an uncontrolled dose from an unregulated source.
Product Quality and Contamination
Because MT-2 is not manufactured by any licensed pharmaceutical company, every vial a user purchases comes from an unregulated lab. This introduces risks that have nothing to do with the peptide itself. A qualitative study of online user forums found that discussions around MT-2 frequently involved sharing information about product preparation, dosing regimens, and sourcing, often in a context rife with misinformation.14PubMed. Melanotan II User Experience: A Qualitative Study of Online Discussion Forums Researchers noted that users faced hazards beyond the drug’s pharmacology, including the risk of infectious disease transmission from shared or improperly handled injection equipment, use of potentially contaminated products, and concurrent use of tanning beds.
Chemical analyses of MT-2 products purchased online have found variable purity levels, with some batches containing degradation products, synthesis byproducts, or incorrect amounts of the active peptide. A user injecting what they believe is a carefully measured dose may be receiving significantly more or less than intended, or introducing unknown contaminants directly into their body. The combination of an inherently unpredictable drug with unpredictable product quality is a large part of why health authorities in the United States, United Kingdom, European Union, and Australia have issued warnings against its use.
Who Uses MT-2 and Why
Research into the user community paints a consistent picture. The primary motivation is cosmetic: people want a tanned appearance, often in anticipation of beach holidays or bodybuilding competitions where a dark tan is considered aesthetically desirable.14PubMed. Melanotan II User Experience: A Qualitative Study of Online Discussion Forums Many users are fair-skinned individuals from Northern European countries who struggle to tan naturally. The appeal of MT-2 is that it promises a result their genetics would otherwise prevent, and for many users, it delivers on that promise in the short term.
The secondary motivations are the appetite suppression and libido enhancement, which some users frame as welcome bonuses rather than side effects. In bodybuilding communities especially, the appetite-suppressing properties are valued during cutting phases when athletes are trying to lose body fat while preserving muscle. The libido effects are discussed openly and sometimes treated as a primary reason for use.
What the forums and case reports consistently reveal is that most users dramatically underestimate the risks. Many adopt a “start low and go slow” dosing philosophy, which gives a sense of control, but the most serious reported adverse events (rhabdomyolysis, dysplastic nevi, melanoma) have occurred in users who were following typical recreational dosing protocols. There is no established “safe” dose, because the compound has never completed the clinical trial process that would define one.
What Happens When You Stop
One of the common questions in user communities is how long the tan lasts after discontinuing MT-2. Anecdotally, the pigmentation persists for roughly four to eight weeks after the last dose, then fades gradually as melanocytes undergo their normal turnover cycle. This is broadly consistent with how natural tanning fades, since the melanin is deposited in skin cells that are continuously replaced. Some users report that areas of uneven pigmentation or darkened moles take longer to normalize, and there are anecdotal accounts of moles remaining permanently darkened even after the surrounding skin returns to baseline.
Whether the biological changes induced by MT-2 are fully reversible is genuinely unknown. The peptide-induced dysplastic nevi documented in case reports did not revert on their own; they had to be surgically excised and monitored. If MT-2 has triggered genuine cellular changes in melanocytes, stopping the drug removes the ongoing stimulus but does not necessarily undo what has already happened. This is a critical point that is poorly understood even among regular users, many of whom assume that any negative effects will simply go away when they stop injecting.
Why No Regulatory Agency Has Approved It
MT-2 was originally developed with the intention of creating a sun-protective tanning agent, and early preformulation work explicitly framed it as a “potential skin cancer chemopreventive peptide.”1PubMed. Preformulation studies with melanotan-II: a potential skin cancer chemopreventive peptide The irony of its current situation is hard to miss: a compound designed to prevent skin cancer is now associated with case reports of melanoma. The pharmaceutical development pathway instead yielded two selective spinoff drugs (afamelanotide for pigmentation, bremelanotide for sexual dysfunction), while the parent compound was abandoned because its nonselective receptor binding made the side-effect profile unacceptable for a regulated medicine.
Every major drug regulatory agency that has commented on MT-2 has warned against its use. The products sold online are classified as unapproved drugs, and importing them is technically illegal in most jurisdictions. Despite this, enforcement is sporadic, and the peptide remains readily available through online vendors who ship discreetly. The gap between what regulators say and what consumers can access remains wide, and it is the individual user who absorbs all of the risk.